Evidence map›Paper›PMID 22535637›Full record

ArticleHepatology (Baltimore, Md.)2012

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.

Diana Vetter, Michal Cohen-Naftaly, Augusto Villanueva, Youngmin A Lee, Peri Kocabayoglu, Rebekka Hannivoort, Goutham Narla, Josep M Llovet, Swan N Thung, Scott L Friedman

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Krüppel-like factors in hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 4 countries.

Diana VetterDepartment of Medicine/Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Michal Cohen-Naftaly
Augusto Villanueva
Youngmin A Lee
Peri Kocabayoglu
Rebekka Hannivoort
Goutham Narla
Josep M Llovet
Swan N Thung
Scott L Friedman
Icahn School of Medicine at Mount Sinai · USConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ES

Funding

The Role of KLF6 in Hepatic FibrosisR01DK056621 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FRIEDMAN, SCOTT L. · 2000 to 2019
$6.2M
THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSISR01DK037340 · NIDDK · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI FRIEDMAN, SCOTT L. · 1987 to 2010
$3.5M
Project 2P20AA017067 · NIAAA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FRIEDMAN, SCOTT L. · 2008 to 2012
$2.5M
Integrative genomic analysis in hepatocellular carcinomaR01DK076986 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LLOVET, JOSEP M · 2007 to 2011
$1.3M
NIAAA NIH HHS P20 AA017067NIDDK NIH HHS R01 DK037340NIDDK NIH HHS R01 DK056621NIDDK NIH HHS R01 DK076986NIDDK NIH HHS R01DK076986NIDDK NIH HHS R01DK37340NIDDK NIH HHS R01DK56621
6 · The paper itself

Abstract

unlabelledKLF6-SV1 (SV1), the major splice variant of KLF6, antagonizes the KLF6 tumor suppressor by an unknown mechanism. Decreased KLF6 expression in human hepatocellular carcinoma (HCC) correlates with increased mortality, but the contribution of increased SV1 is unknown. We sought to define the impact of SV1 on human outcomes and experimental murine hepatocarcinogenesis and to elucidate its mechanism of action. In hepatitis C virus (HCV)-related HCC, an increased ratio of SV1/KLF6 within the tumor was associated with features of more advanced disease. Six months after a single injection of diethylnitrosamine (DEN), SV1 hepatocyte transgenic mice developed more histologically advanced tumors, whereas Klf6-depleted mice developed bigger tumors compared to the Klf6fl(+/+) control mice. Nine months after DEN, SV1 transgenic mice with Klf6 depletion had the greatest tumor burden. Primary mouse hepatocytes from both the SV1 transgenic animals and those with hepatocyte-specific Klf6 depletion displayed increased DNA synthesis, with an additive effect in hepatocytes harboring both SV1 overexpression and Klf6 depletion. Parallel results were obtained by viral SV1 transduction and depletion of Klf6 through adenovirus-Cre infection of primary Klf6fl(+/+) hepatocytes. Increased DNA synthesis was due to both enhanced cell proliferation and increased ploidy. Coimmunoprecipitation studies in 293T cells uncovered a direct interaction of transfected SV1 with KLF6. Accelerated KLF6 degradation in the presence of SV1 was abrogated by the proteasome inhibitor MG132.

conclusionAn increased SV1/KLF6 ratio correlates with more aggressive HCC. In mice, an increased SV1/KLF6 ratio, generated either by increasing SV1, decreasing KLF6, or both, accelerates hepatic carcinogenesis. Moreover, SV1 binds directly to KLF6 and accelerates its degradation. These findings represent a novel mechanism underlying the antagonism of tumor suppressor gene function by a splice variant of the same gene.

Indexed as

Gene Expression Regulation, NeoplasticAnalysis of VarianceAnimalsCarcinoma, HepatocellularDiethylnitrosamineDisease Models, AnimalDisease ProgressionHepacivirusHepatitis B virusHepatocytesHumansKruppel-Like Factor 6Kruppel-Like Transcription FactorsLiver NeoplasmsMaleMembrane GlycoproteinsDiethylnitrosamineKlf6 protein, mouseKruppel-Like Factor 6Kruppel-Like Transcription FactorsMembrane GlycoproteinsNerve Tissue ProteinsProto-Oncogene ProteinsSv2a protein, mouse

Identifiers

PMID22535637
PMCPMC3412196
OpenAlexW2101167540

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.